• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of novel therapeutic strategy based on malignant nature of colorectal cancer

Research Project

Project/Area Number 16591313
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Digestive surgery
Research InstitutionOsaka University

Principal Investigator

YAMAMOTO Hirofumi  Osaka University, Graduate School of Medicine, Assistant, 医学系研究科, 助手 (30322184)

Co-Investigator(Kenkyū-buntansha) SEKIMOTO Mistugu  Osaka University, Graduate School of Medicine, Associate Professor, 医学系研究科, 助教授 (10273658)
IKEDA Masataka  Osaka University, Graduate School of Medicine, Assistant, 医学系研究科, 助手 (80335356)
Project Period (FY) 2004 – 2005
Project Status Completed (Fiscal Year 2005)
Budget Amount *help
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2005: ¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 2004: ¥1,900,000 (Direct Cost: ¥1,900,000)
Keywordsantisense cyclin D1 / TCF decoy / dominant negative TCF / colorectal cancer / liver metastasis / Wnt signal / cyclin D1
Research Abstract

Beta-catenin and TCF complex is activated in a variety of gastrointestinal cancer. The down stream of this way contains cancer related gene including cyclin D1,MMP7,c-myc. To block this pathway may be useful strategy against cancer. We target TCF transcription and cyclin D1 oncogene.
1.Adnovirus dominant negative TCF
Adenovirus dominant negative TCF inhibited TCF transcription activity and the promoter activities of down stream genes including cyclin D1,MMP7,c-myc. It also inhibited in vivo subcutaneous tumor growth and liver metastasis. Therapeutic model for xenograft was also successful. These findings suggest that Adenovirus dominant negative TCF may be useful strategy for tumors that display high TCF transcription activity.
2.TCF decoy
To block TCF activity in safer way, we developed a novel TCF DNA decoy. In vitro assays indicated it inhibited TCF activity and the promoter activities of down stream genes including cyclin D1,MMP7,c-myc. successfully. It inhibited growth of tumor cell, but not non-tumor cells. However problem still remains with regard to its stability in vivo. FITC labeling revealed TCF decoy accumulate into nucleus within 24 hr and remained till 48-72 hr. These findings will be published in Mol Cancer Ther (in press).
3.Antisense cyclin D1
Adenovirus antisense cyclin D1 inhibited tumor growth and tumor associated vessels. One of the mechanism for anti-tumor vessel is a direct effects of antisense to cyclin D1 on vascular endothelial cells. As another mechanism, cyclin D1 inhibition caused inhibition of STAT-3 transcription factor, which leaded to inhibition of VEGF promoter activity. This occurs in a certain tumor cell type. These findings will be published in Clin Cancer Res (in press).

Report

(3 results)
  • 2005 Annual Research Report   Final Research Report Summary
  • 2004 Annual Research Report
  • Research Products

    (7 results)

All 2004 Other

All Journal Article (7 results)

  • [Journal Article] Wntシグナルを標的とした治療2004

    • Author(s)
      関洋介, 山本清文, 他
    • Journal Title

      現代医療 36(7)

      Pages: 1373-1380

    • Related Report
      2004 Annual Research Report
  • [Journal Article] Antisense to Cyclin D1 Inhibits VEGF-Stimulated Growth of Vascular Endothelial Cells. Implication of Tumor Vascularization.

    • Author(s)
      Yasui M., Yamamoto., et al.
    • Journal Title

      Clin Cancer Res. (in press)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Construction of a novel DNA decoy that inhibits the oncogenic □-catenin/TCF pathway.

    • Author(s)
      Seki Y., Yamamoto., et al.
    • Journal Title

      Mol Cancer Ther. (in press)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Antisense to Cyclin D1 Inhibits VEGF-Stimulated Growth of Vascular Endothelial Cells. Implication of Tumor Vascularization.

    • Author(s)
      Yasui M., Yamamoto H., et al.
    • Journal Title

      Clin Cancer Res. (in press)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Construction of a novel DNA decoy that inhibits the oncogenic □-catenin/TCF pathway.

    • Author(s)
      Seki Y., et al.
    • Journal Title

      Mol Cancer Ther. (in press)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2005 Final Research Report Summary
  • [Journal Article] Antisense to Cyclin D1 Inhibits VEGF-Stimulated Growth of Vascular Endothelial Cells. Implication of Tumor Vascularization

    • Author(s)
      Yasui M, Yamamoto H, Ngan Chew Yee, Bazarragchaa D, Sugita Y, Fukunaga H, Gu J, Maeda M, Takemsa I, Ikeda M, Fujio Y, Sekimoto M. Matsuura N, I.Bernard Weinstein, Monden M.
    • Journal Title

      Clinical Cancer Research (in press)

    • Related Report
      2005 Annual Research Report
  • [Journal Article] Construction of a novel DNA decoy that inhibits the oncogenic β-catenin/TCF pathway

    • Author(s)
      Seki Y, Yamamoto H, Ngan Chew Yee, Yasui M, Tomita N, Kitani K, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Chris Albanese, Kaneda Y, Richard G Pestell, Monden M.
    • Journal Title

      Molecular Cancer Therapeutics (in press)

    • Related Report
      2005 Annual Research Report

URL: 

Published: 2004-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi